Inhalation Sciences wins place on prestigious EU-funded Life Science Investment Hotlist
Stockholm is a world-famous hotspot for game-changing, early-stage life science companies—but which really have the most commercial potential? Funded by the EU European Regional Development Fund, the Invest Stockholm group selects the region’s most commercially innovative companies—and has now chosen Inhalation Sciences (ISAB) for the list.Business and science leaders from all over the globe flock to Stockholm and Uppsala to find solutions in the region’s thriving, entrepreneurial Life Sciences hub. Now Stockholm City’s Invest Stockholm group, funded by the EU, formally curate a list of the